-
The Seville-based biotech closes a private investment round of 500,000 euros and receives 2.5 million euros in non-repayable funding from CDTI thanks to the European Seal of Excellence.
-
The round, ratified on December 17, brings in Dr. Leni Ramos (San Francisco) as an investor and new Chief Medical Officer (CMO) and co-CEO of the company.
-
The company’s shareholder base includes world-class figures such as Francisco León, who sold Provention Bio to Sanofi for close to three billion dollars.
-
PlusVitech launches a Phase 2 clinical trial with 42 patients with advanced lung cancer after being awarded Best Startup at the WBAF in Istanbul on December 9.
Seville, December 22, 2025. – PlusVitech, a Spanish biotechnology company specializing in disruptive oncology therapies, has closed the year with a key financial and corporate milestone by securing total funding of three million euros. This capital injection is the result of a hybrid strategy that combines European institutional backing with the entry of international smart money.
The financing transaction was formalized last Wednesday, December 17, coinciding with the company’s General Shareholders’ Meeting. It is broken down into the granting of 2.5 million euros in non-repayable funding from CDTI—thanks to the Seal of Excellence of the European Innovation Council (EIC)—and the closing of a private investment round of 550,000 euros.
Star appointment: Leni Ramos
The December round has brought a key addition: Dr. Leni Ramos (San Francisco), who joins the shareholding structure and assumes the role of co-CEO and Chief Medical Officer (CMO).
Dr. Ramos explains her dual commitment (financial and professional) to the company:
“I decided to invest in and join PlusVitech because its combined drug repurposing and nanotechnology approach is one of the smartest strategies I have seen to tackle cancer. We have the science, the team, and now the resources to demonstrate it in the clinic.”
Ramos strengthens a robust management team made up of Fran Guillén (General Manager), a prominent serial entrepreneur and Vice President of AABAN; Carmen Lara (COO), an experienced businesswoman and MBA; and Jörg Landwehr (Licensing Director), former executive at PharmaMar and Roche Oncology Germany, among others.
These new investors join a shareholder base of the highest international prestige. PlusVitech already had the backing of figures such as Francisco León (Washington DC), co-founder of Provention Bio, a company acquired by pharmaceutical group Sanofi in a transaction valued at more than three billion dollars; other prestigious private investors such as Sebastián Urbán of Asterion Partners; as well as the fund CGP Capital, founded by Luis Prieto and Mehdi Chouikh (former founders of Abatel) together with Borja García; the health-focused fund Homu Health; and the renowned Madrid law firm ILP Abogados.
Technology partnership and Phase 2 trial
The funds will allow the immediate launch of a Phase 1/2 clinical trial with 42 patients with advanced lung cancer, focused on validating the efficacy of the PVT-01 treatment. In parallel, the company is finalizing its collaboration with the Finnish technology company Nanoform. This alliance aims to develop a new nanoparticle-based formulation capable of achieving higher drug loading with improved bioavailability, simplifying dosing and optimizing costs.
Fran Guillén, General Manager, highlights the scope of the project:
“Securing these three million euros represents a giant step forward, allowing us, on the one hand, to carry out the clinical trial and, on the other, to complete our new formulation with Nanoform.”
For his part, Dr. Vicente Salinas, CEO of PlusVitech, emphasizes the clinical impact:
“This Phase 1/2 trial with 42 patients will allow us to demonstrate, in an official clinical study, the spectacular preliminary results we had already achieved in patients.”
International recognition
This momentum caps a historic month of December for the company. Last Tuesday, December 9, PlusVitech won first prize at the World Business Angels Investment Forum (WBAF) in Istanbul. Before investors from more than 30 countries, the company was recognized as the winning and most promising startup in the global ecosystem.
About PlusVitech
PlusVitech is a biotechnology company focused on drug repurposing and the development of new nanotechnology-based formulations for cancer treatment. Its innovative approach seeks to reduce development timelines and costs for new therapies, prioritizing patient safety and efficacy.
More information at https://www.plusvitech.com/
